COVID19 – From SAMHSA: Tips For Social Distancing, Quarantine, And Isolation During An Infectious Disease Outbreak 

The Caring Ambassadors Lung Cancer Program provides this website to help you and your loved ones understand your disease and some of the health care options available to you.
Knowledge empowers you to ask the necessary questions to become your own best advocate.

The Caring Ambassadors Hepatitis C Program uses a unique approach in our work to address the elimination of viral hepatitis and specifically hepatitis C.
We are honored to serve the community to help eliminate the largest infectious disease outbreak of our time

MY CHOICES© is a tool to help you recognize and act upon what you can control in your health care journey to achieve optimal healing, regardless of the illness you face. It contains elements of a guide book, health planner, journal, and activity book to help orient you to and plan for the journey ahead.

AmazonSmile is a website operate by Amazon with the same products, prices and shopping features as Amazon.com. The difference is that when you shop on AmazonSmile, the AmazonSmile Foundation will donate 0.5% of the purchase price of eligible products. 

The time is now. 71 million people worldwide are living with chronic Hepatitis C right now. It is the largest chronic infectious disease outbreak of our time…and it’s curable. Talk to your doctor about treatment for your Hepatitis C, and don’t take no for an answer

The BIGG ELIMINATION TRIBUTE PROJECT is a FREE, online, self-paced 7-module series has been developed to help establish replicable frameworks for HCV prevention & education using harm reduction strategies. 

Weekly News Update.
Caring Ambassadors Program provides 3 weekly news updates covering Lung Cancer News, Hepatitis C News, and My Choices© Update. Receive them delivered weekly to your inbox.

My Choices© Update
Week Ending June 1, 2020

4 Small Ways to Practice Gratitude Every Day
“You probably have a general inkling that gratitude is good—and that having a gratitude practice might be good for you.”

All of the Nutrition Facts, Health Benefits, and Risks of Taking Bee Pollen
“It could be good to add to your diet, but there are some side-effects you need to know.”

The best exercises for your bones
“Certain types of exercise can increase muscle mass, which in turn enhances strength, muscle control, balance, and coordination. Good balance and coordination can mean the difference between falling—and suffering a fracture—and staying on your feet. Strong evidence shows that regular physical activity can reduce falls by nearly a third in older adults at high risk of falling.”

Few US adults participate in all recommended healthy behaviors
“Less than 7% of U.S. adults engaged in all five healthy behaviors recommended by public health institutions, including HHS, the CDC, the American Lung Association and the American Cancer Society, researchers reported.”

7 Simple Ways to Elevate Your Energy and Focus Right Now
“Feeling a little lower on energy lately? Not able to focus as well? With the pandemic continuing to cause disruptions to everyday life, it’s little wonder. Your focus and attention are being pulled in so many different directions that the additional stress can easily zap your batteries and cause that mind to wander.”

What does a healthy diet look like?
“What’s the healthiest way to eat? It depends on whom you ask. Many medical and nutrition experts claim to know the “perfect” way to eat for health, yet some of these dietary advocates disagree with each other in some fundamental ways. So, who’s right . . . and who’s wrong?”

Is all sugar the same? The difference between good and bad sugars
“Agave. Honey. Maple syrup. All are touted as “better” alternatives to white cane sugar, but none of them are actually good for you.”

VIDEO

Health Insurance Options During COVID-19; An Integrative Approach To Your Health
“How to navigate health insurance in the midst of the coronavirus pandemic; How chronic inflammation impacts the body.”

Hepatitis C News
Week Ending June 1, 2020

Opt-Out Hep C Testing in ERs: Great Way to ID People With the Virus
‘Establishing a program of providing blanket opt-out hepatitis C virus (HCV) testing in hospital emergency departments is an effective means of detecting the virus, especially among those younger than 55 years old, according to a new Centers for Disease Control and Prevention (CDC) analysis.’

Hepatitis Elimination Spotlight: Alaska Takes on Hepatitis in Alaska Native/American Indian Population Across the State
‘American Indian and Alaska Native (AI/AN) communities are disproportionately affected by hepatitis C virus (HCV). The most recent national data show AI/AN people as the racial/ethnic group with the highest rates of both acute HCV infection as well as HCV-related deaths. Responding to these health disparities and building on the previous success of hepatitis A and B elimination and linkage of AN persons with chronic HBV to care and liver cancer screening, the Alaska Native Health Tribal Consortium (ANTHC) is committed to hepatitis C elimination.’

Identifying Seroprevalence and Risk Factors for HCV in Pregnant Women

‘New strategies are needed for identifying mothers with hepatitis C virus (HCV) antibodies and the neonates susceptible to maternal transmission of HCV, according to results of a study published in Obstetrics & Gynecology. The number of reported cases of HCV has been rising annually, particularly among young women, leading to an increase in the number of neonates born to mothers who are HCV positive.’

Taxpayers paid to develop remdesivir but will have no say when Gilead sets the price

‘The drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, remdesivir, started as a reject, an also-ran in the search for antiviral drugs. Its path to relevance didn’t begin until Robert Jordan plucked it from mothballs. A Gilead scientist at the time, Jordan convinced the company seven years ago to let him assemble a library of 1,000 castoff molecules in a search for medicines to treat emerging viruses. Many viral illnesses threaten human health but don’t attract commercial interest because they lack potential for huge drug sales.’

Cost-effective drug found to prevent hepatitis C transmission in kidney transplantation

‘A short course of direct-acting anti-viral prophylaxis may be effective in preventing transmission of hepatitis C virus from kidney donors to recipients, according to study results presented virtually at the American Transplant Congress. Citing previous trials that indicated a 12-week course of direct-acting anti-viral [DAA] drugs is effective in treating hepatitis C virus [HCV] transmission from infected donors to HCV-negative recipients, Gaurav Gupta, MD, of Virginia Commonwealth University, told the audience that translating these trials into real-life practice can be challenging.’

Lung Cancer News
Week Ending June 1, 2020

ASCO Presentations Highlight Advances in Antibody Treatments for Molecularly Defined Lung Cancers
“NEW YORK – Three antibody drugs have demonstrated promising activity in metastatic non-small cell lung cancer patients with molecularly differentiated tumors in studies presented at the American Society of Clinical Oncology’s virtual annual meeting.”

ALK-Rearranged NSCLC Linked to Higher Venous and Arterial Thrombotic Risk
“NSCLC patients who have an ALK rearrangement may have an increased risk for venous thromboembolism and arterial thrombosis, a retrospective cohort study found. Patients with non–small cell lung cancer (NSCLC) who have an ALK rearrangement may have an increased risk for venous thromboembolism and arterial thrombosis compared with NSCLC patients without an ALK rearrangement, according to a retrospective cohort study. The study findings were recently published in the Journal of Thoracic Oncology.”

Lurbinectedin Successful Second-line Treatment for Small-cell Lung Cancer Patients After First-line Failure
“Lurbinectedin may be a viable option as a second-line treatment for small-cell lung cancer (SCLC) patients whose first-line therapy was unsuccessful, a study found.”

Tagrisso shows ‘unprecedented’ disease free survival in lung cancer
“According to AstraZeneca, its EGFR inhibitor Tagrisso (osimertinib) has shown ‘unprecedented disease-free survival’ in the adjuvant treatment of patients with EGFR-mutated lung cancer.”

FDA Approves Ramucirumab Injection in Combination with Erlotinib for NSCLC
“The FDA has approved a 10 mg/mL solution of ramucirumab injection (Cyramza) in combination with erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, according to Eli Lilly and Company, the developer of the injection.”

Taking Aim at TIGIT, a New Immunotherapy Approach to Non-Small Cell Lung Cancer
“The 2020 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1).”

ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLC
“On Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study. The updated data show an increased 5-year survival rate with Alecensa® (alectinib) compared with crizotinib, reinforcing the value of Alecensa to improve outcomes for patients with this disease.”

IASLC Survey Illustrates Current Barriers to Molecular Testing in Lung Cancer
“The rate of global molecular testing is low and is limited by a number of factors, including cost, quality, turn-around time, access, and lack of awareness of testing, according to survey results published in the Journal of Thoracic Oncology.1″

Treatment Decisions for Lung Cancer During COVID-19 Require Balancing Exposure Risk, Effective Care
“Because patients with lung cancer have the highest reported mortality rate due to coronavirus disease 2019 (COVID-19), oncology teams may struggle to balance effectively caring for these patients while avoiding exposure risks and safety.1″